Drug & intervention

triamcinolone

RxCUI 10759

Clinical trials5
Recruiting0
Related conditions9
Synonyms16

Understanding this RxNorm record

RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.

Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.

Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Triamcinolone

Triamcinolone is a glucocorticoid used to treat certain skin diseases, allergies, and rheumatic disorders among others. It is also used to prevent worsening of asthma and chronic obstructive pulmonary disease (COPD). It can be taken in various ways including by mouth, injection into a muscle, and inhalation. Common side effects with long-term use include osteoporosis, cataracts, thrush, and muscle weakness. Serious side effects may include psychosis, increased risk of infections, adrenal suppression, and bronchospasm. Use in pregnancy is generally safe. It works by decreasing inflammation and immune system activity. Triamcinolone was patented in 1956 and came into medical use in 1958. It is available as a generic medication. In 2023, it was the 108th most commonly prescribed medication in the United States, with more than 6 million prescriptions.

Read on Wikipedia ↗ Wikidata Q1074056 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

5 shown
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIANCT02451748 · 2015-08-01
COMPLETED
Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind EyeNCT01404364 · 2010-01-01
COMPLETED
The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic RetinopathyNCT00849537 · 2008-04-01
UNKNOWN
Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular EdemaNCT00682539 · 2007-10-01
COMPLETED
Lung Health Study IINCT00000569 · 1993-09-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.